v3.26.1
Consolidated Statements of Shareholders' Equity - CAD ($)
$ in Thousands
The 2026 warrants [member]
Issued capital [member]
The 2026 warrants [member]
Capital reserve [member]
The 2026 warrants [member]
Accumulated other comprehensive income [member]
The 2026 warrants [member]
Retained earnings [member]
The 2026 warrants [member]
April private placement [member]
Issued capital [member]
April private placement [member]
Capital reserve [member]
April private placement [member]
Accumulated other comprehensive income [member]
April private placement [member]
Retained earnings [member]
April private placement [member]
October private placement [member]
Issued capital [member]
October private placement [member]
Capital reserve [member]
October private placement [member]
Accumulated other comprehensive income [member]
October private placement [member]
Retained earnings [member]
October private placement [member]
Pre-funded warrants [member]
Issued capital [member]
Pre-funded warrants [member]
Capital reserve [member]
Pre-funded warrants [member]
Accumulated other comprehensive income [member]
Pre-funded warrants [member]
Retained earnings [member]
Pre-funded warrants [member]
Issued capital [member]
Capital reserve [member]
Accumulated other comprehensive income [member]
Retained earnings [member]
Total
Balance (in shares) at Dec. 31, 2022                                         8,796,494        
Balance at Dec. 31, 2022                                         $ 288,871 $ 17,892 $ 525 $ (180,779) $ 126,509
Statement Line Items [Line Items]                                                  
Other comprehensive earnings for the period                                         0 0 (2,082) 0 (2,082)
Net loss for the period                                         0 0 0 (64,666) (64,666)
Share-based payment expense                                         0 1,226 0 0 1,226
Directors’ fees paid in deferred share units                                         0 595 0 0 595
Private placement                                         $ (284) 0 0 0 (284)
Proceeds from issuance of shares, net of transaction costs (Note 16) (in shares)                                         4,886,364        
Proceeds from issuance of shares, net of transaction costs (Note 16)                                         $ 14,077 5,883 0 0 19,960
Exercise of share based payment arrangement (Note 13) (in shares)                                         763        
Exercise of share based payment arrangement (Note 13)                                         $ 17 (17) 0 0 0
Settlement of interest on 2028 Notes (Notes 11 and 17) (in shares)                                         165,200        
Settlement of interest on 2028 Notes (Notes 11 and 17)                                         $ 795 0 0 0 795
Settlement transaction costs on 2028 Notes (in shares)                                         19,375        
Settlement transaction costs on 2028 Notes                                         $ 240 0 0 0 240
Convertible notes conversion (in shares)                                         92,136        
Convertible notes conversion                                         $ 998 0 0 0 998
Settlement of easement (in shares)                                         2,500        
Settlement of easement                                         $ 7 0 0 0 7
Balance (in shares) at Dec. 31, 2023                                         13,962,832        
Balance at Dec. 31, 2023                                         $ 304,721 25,579 (1,557) (245,445) 83,298
Statement Line Items [Line Items]                                                  
Other comprehensive earnings for the period                                         0 0 6,196 0 6,196
Net loss for the period                                         0 0 0 (29,447) (29,447)
Share-based payment expense                                         0 1,739 0 0 1,739
Directors’ fees paid in deferred share units                                         $ 0 29 0 0 29
Proceeds from issuance of shares, net of transaction costs (Note 16) (in shares)                                         443,225        
Proceeds from issuance of shares, net of transaction costs (Note 16)                                         $ 1,221 0 0 0 1,221
Warrants issued in connection with 2027 Notes, net of transaction costs (Note 17)                                         $ 0 605 0 0 605
Performance based incentive payment (Note 17) (in shares)                                         41,314        
Performance based incentive payment (Note 17)                                         $ 134 0 0 0 134
Exercise of share based payment arrangement (Note 13) (in shares)                                         151,066        
Exercise of share based payment arrangement (Note 13)                                         $ 1,104 (1,104) 0 0 0
Settlement of interest on 2028 Notes (Notes 11 and 17) (in shares)                                         210,760        
Settlement of interest on 2028 Notes (Notes 11 and 17)                                         $ 543 0 0 0 543
Balance (in shares) at Dec. 31, 2024                                         14,809,197        
Balance at Dec. 31, 2024                                         $ 307,723 26,848 4,639 (274,892) 64,318
Statement Line Items [Line Items]                                                  
Other comprehensive earnings for the period                                         0 0 (3,141) 0 (3,141)
Net loss for the period                                         0 0 0 (133,465) (133,465)
Share-based payment expense                                         0 1,453 0 0 1,453
Directors’ fees paid in deferred share units                                         $ 0 254 0 0 254
Exercise of warrants (in shares) 2,481,786                             5,330,000                  
Exercise of warrants $ 13,925 $ 0 $ 0 $ 0 $ 13,925                     $ 7,302 $ 0 $ 0 $ 0 $ 7,302          
Exercise of broker warrants, restricted share units and stock options (Note 16) (in shares)                                         107,860        
Exercise of broker warrants, restricted share units and stock options (Note 16)                                         $ 287 (125) 162
Private placement (in shares)           3,125,000         46,000,000                            
Private placement           $ 3,421 $ 109 $ 0 $ 0 $ 3,530 $ 24,642 $ 4,604 $ 0 $ 0 $ 29,246                    
Shares issued on settlement of 2028 and 2027 Notes (Note 11) (in shares)                                         27,128,396        
Shares issued on settlement of 2028 and 2027 Notes (Note 11)                                         $ 62,666 0 0 0 62,666
Balance (in shares) at Dec. 31, 2025                                         98,982,239        
Balance at Dec. 31, 2025                                         $ 419,966 $ 33,143 $ 1,498 $ (408,357) $ 46,250